Compare Travere Therapeutics Inc. Common Stock (TVTX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B), while State Street SPDR S&P Biotech ETF trades at $147.19 (market cap $10.05B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2× Travere Therapeutics Inc. Common Stock's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (10,367,649 versus 2,060,842). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| TVTX | XBI | |
|---|---|---|
Market Cap | $5.02B | $10.05B |
Volume | 2,060,842 | 10,367,649 |
Sector | Health | Broad Market / Factor |
52-Week High | $67.52 | $169.55 |
52-Week Low | $26.79 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $5.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
